-
Environmental monitoring data - the "lifeline" of pharmaceutical production that cannot be ignored!
Time of Update: 2022-05-05
Only through complete, high-quality, true and accurate data monitoring can we ensure that the pollutants in the pharmaceutical process better meet the relevant national standards .
-
interpack launches a new theme, and the number of exhibition registrations in 2023 has reached 85%
Time of Update: 2022-05-04
As an interpack China exhibition, swop is a grand event for the processing and packaging machinery industry in China and even in Asia, providing customers with a good product and technology display platform .
-
The new situation and new ideas will empower the sustainable development of the green pharmaceutical industry. The first China Green Pharmaceutical Industry Summit will be held in Wuhan!
Time of Update: 2022-05-04
[Pharmaceutical Network Conference Forum] The pharmaceutical industry is both a traditional industry and a strategic emerging industry . Vigorously developing the pharmaceutical industry, creating
-
Announcement on the resumption of the 13th Shanghai International Chemical Equipment Expo
Time of Update: 2022-05-04
In order to reduce the impact of the epidemic on the effect of the exhibition, we have focused on strengthening online publicity, promotion and advertising, while deepening media cooperation, and actively communicating and cooperating with relevant chemical industry associations and societies in various provinces and cities.
-
655 varieties passed the consistency evaluation, and tablets and capsules are still the focus
Time of Update: 2022-05-04
Common problems in pharmacy for consistency evaluation of tablets and capsules include research on impurities of raw materials, particle size research, crystal form research, excipient research, packaging material research, formulation technology research, quality research and stability research, etc.
-
The concurrent meeting of the 87th API China Pharmaceutical Equipment Exhibition is freshly released
Time of Update: 2022-05-04
[Pharmaceutical Network Conference Forum] On October 12-14, 2021, the 87th China International Pharmaceutical API/Intermediate/Packaging/Equipment Fair (API China) will cooperate with the 25th China International Pharmaceutical (Industry) Exhibition The conference and technical exchange meeting (CHINA-PHARM) (←Click to enter the pre-registration channel) will be held at the Wuhan International Expo Center at the same time .
-
On October 12, API China API China & CHINA-PHARM Pharmaceutical Industry Exhibition will meet you in Wuhan!
Time of Update: 2022-05-04
Dear exhibitors, visitors and industry colleagues: The 87th China International Pharmaceutical API/Intermediate/Packaging/Equipment Fair (API China) and the 25th China International Pharmaceutical (Industry) Exhibition and Technology Exchange Conference (CHINA-PHARM) will be held on October 12-14 at Wuhan International Expo Center as scheduled .
-
Eli Lilly's dual agonist tirzepatide has no obvious advantage over competitor drugs!
Time of Update: 2022-05-03
While ICER reviewers said tirzepatide had a clear benefit over background therapy, experts were divided over the drug's benefit over Novo Nordisk Ozempic and Eli Lilly/Boehringer Ingelheim Jardiance .
-
Jilin Aodong Holding Subsidiary Obtained 8 National Standard Chinese Medicine Formula Granules Listing Recording Certificates
Time of Update: 2022-05-03
On February 7, Jilin Aodong announced that its holding subsidiary, Yanbian Pharmaceutical, had received 8 national standards for the "Listing Certificate of Traditional Chinese Medicine Formula Granules" .
As of the date of this announcement, it has obtained 99 "Chinese Medicine Formula Granules Listing Recording Certificates" .
-
Fosfomycin tromethamine powder, a subsidiary of Northeast Pharmaceuticals, passed the consistency evaluation of generic drugs
Time of Update: 2022-05-03
On the evening of February 10, Northeast Pharmaceuticals announced that its wholly-owned subsidiary, No.
It has passed the consistency evaluation of generic drugs .
Fosfomycin tromethamine powder is suitable for the treatment of acute simple urinary tract infection caused by sensitive Escherichia coli, Enterococcus faecalis, Klebsiella pneumoniae, Citrobacter, Enterobacter, and Proteus mirabilis etc.
-
Protein-degrading drugs and molecular glues account for one-third of the "Drug Hunters" annual list of small molecules
Time of Update: 2022-05-03
Revolution Medicines' KRAS G12C inhibitorRevolution Medicines' KRAS G12C inhibitorImage source: Reference [1]RM-018, developed by Revolution Medicines, is a small molecule inhibitor that inhibits the activity of KRAS G12C mutants by binding to their activated state .
-
Mycoplasma pneumoniae pneumonia treatment: which drug is azithromycin relegated to the second line of choice?
Time of Update: 2022-05-03
From the "Guidelines for the Diagnosis and Treatment of Community-Acquired Pneumonia in Chinese Adults (2016 Edition)" [2], azithromycin (and clarithromycin) have taken a back seat in the treatment of Mycoplasma pneumoniae pneumonia, replaced by doxycycline, mino Cyclic or respiratory quinolones, and macrolides in areas with low rates of mycoplasma resistance .
-
The Role of the Oncology Drug Advisory Committee (ODAC) in FDA Review
Time of Update: 2022-05-03
What kind of organization is ODAC, and how much influence will it have on the FDA's review results?introduction:Picture from: US FDA official websiteAC and ODACAC and ODACOrganizational Structure and Main ResponsibilitiesOrganizational Structure and Main ResponsibilitiesThere are many disciplines involved in drug regulation, and with the acceleration of information updates, the regulatory authorities will also appear powerless .
-
Tianmushan Pharmaceutical expects a net profit loss of 30 million yuan to 37 million yuan in 2021
Time of Update: 2022-05-03
It is expected that the net profit attributable to shareholders of listed companies will be 30 million yuan in 2021, a loss of 3.
52 million yuan compared with the same period last year, and a year-on-year loss of 8.
-
Jiu'an Medical received the decision on administrative supervision measures, the chairman and the secretary were interviewed
Time of Update: 2022-05-03
On the evening of February 14, Jiu'an Medical announced that the company recently received a "Decision on Administrative Supervision Measures" ( Hereinafter referred to as the "Decision"), "Decision on Taking Regulatory Talk Measures against Liu Yi and Wu Tong" (Jin Zheng Jian Measures [2022] No.
-
Buchang Pharmaceutical cancels its wholly-owned subsidiary Zhongxin Shunfa
Time of Update: 2022-05-03
The above matters have been completed, and the company has recently received the "Notice of Deregistration of Foreign-invested Enterprises" issued by Xianyang Market Supervision and Administration Bureau .
-
Tianmushan Pharmaceutical elected Li Feng as chairman and Liu Bo as vice chairman
Time of Update: 2022-05-03
Zhang Yingjun as a supervisor for a term of office from the date of approval at the general meeting of shareholders to the expiration of the eleventh session of the Supervisory Committee .
-
The world's first freeze-dried mRNA vaccine preclinical data release How is the progress of mRNA vaccine at home and abroad?
Time of Update: 2022-05-03
According to the 221-year financial report released by Pfizer earlier, the total revenue of the new crown vaccine Comirnaty reached 36.
Fosun Pharma's 2021 mid-year financial report shows that Fosun Pharma/German BioNTech's mRNA new crown vaccine Fubitai® (BNT162b2) achieved revenue of more than 500 million yuan in Hong Kong and Macau in the first half of 2021 .
-
Included in the U.S. "UVL" list, WuXi Biologics responded urgently
Time of Update: 2022-05-03
S. Department of Commerce's Bureau of Industry and Security (BIS) released an updated "Unverified List (UVL)", which was made public on February 8 .
According to data, from 2017 to 2020, the total proportion of overseas revenue of major domestic CXO listed companies increased from 62.
-
Renfu Medicine's Paracetamol and Oxycodone Sustained-Release Tablets Obtained the Approval Notice for Drug Clinical Trials
Time of Update: 2022-05-03
On February 10, Renfu Pharmaceutical announced that its holding subsidiary, Yichang Renfu, had recently received the "Drug Clinical Trial Approval Letter" approved and issued by the State Drug Administration for acetaminophen and oxycodone sustained-release tablets.
